Botox 100 unit vials
Ended Awarded
- Contract number
- SPE2DB26FZH79
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,775
Award facts
- Contract value 100% obligated
- $2,775.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,775.42 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of BOTOX 100 Unit Vials. The contract is issued on a firm fixed-price basis with an ultimate completion date of November 26, 2025. This delivery order carries no set-aside designation, indicating the vendor competed in an unrestricted procurement environment. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which serves as the underlying vehicle for this delivery order. The parent contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion federal acquisition strategy managed by the Defense Logistics Agency to establish multiple regional prime vendor contractors supplying pharmaceuticals and medical consumables to military healthcare facilities worldwide. Under this structured approach, the Defense Logistics Agency issues firm fixed-price delivery orders for specific products, including branded and generic prescription drugs, biologics, vaccines, and specialty pharmaceuticals, to meet recurring medical supply demands. DMS Pharmaceutical Group's demonstrated performance across numerous delivery orders and its comprehensive product portfolio spanning oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals establish the company's capability to fulfill the specialized pharmaceutical requirements of the federal military medical system on a global basis.
Quick answers
Who was awarded contract SPE2DB26FZH79?
SPE2DB26FZH79 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DB26FZH79 worth?
The government has obligated $2,775 on SPE2DB26FZH79.
Is contract SPE2DB26FZH79 an order under another contract?
Yes. SPE2DB26FZH79 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB26FZH79 competed?
The extent of competition for SPE2DB26FZH79 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award